Clinical Trials
8 trialsNCT03601442 2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available
NCT04809233 2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available
NCT02822495 2023-06-15
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
No longer available
NCT05733650 2023-05-25
Expanded Access Program for Epcoritamab
Genmab
Approved for marketing
NCT05692050 2023-02-03
Expanded Access to Epcoritamab
AbbVie
No longer available
NCT04705454 2021-05-12
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
No longer available
NCT01196208 2020-09-21
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
No longer available
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available